| Literature DB >> 35922094 |
Erik Ronmark1, Ralf Hoffmann2, Viktor Skokic1,3, Maud de Klerk-Starmans2, Fredrik Jaderling3, Pieter Vos2, Maudy C W Gayet2, Hans Hofstraat2, Marco Janssen2, Olof Akre1,3, Per Henrik Vincent4,3.
Abstract
OBJECTIVES: To investigate the impact on efficiency and quality of preprostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared with standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes.Entities:
Keywords: Access to Information; Data Visualization; Decision Support Systems, Clinical
Mesh:
Year: 2022 PMID: 35922094 PMCID: PMC9352979 DOI: 10.1136/bmjhci-2022-100588
Source DB: PubMed Journal: BMJ Health Care Inform ISSN: 2632-1009
Figure 1ISPM dashboard as implemented and used in the prospective, observational study on the impact of a digital solution during the MDTs in the prostate cancer care flow at Karolinska University Hospital. Patient data are fictional and do not originate from a real person. BMI, body mass index; IIEF-5, International Index of Erectile Function; MDT, multidisciplinary therapy; ISPM, IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator; MDT, multidisciplinary therapy; QOL, quality of life; PSA, prostate-specific antigen; PIRADS, Prostate Imaging-Reporting & Data System; MRC, magnetic resonance imaging conference.
Figure 2A Time spent in the MDT meeting per patient in the baseline setting (164 patients) versus the ISPM setting (163 patients). Box plot with median and IQR; whiskers denote IQR. ***P<0.001 (B): interaction between mean time (minutes) spent per patient and number of patients scheduled and discussed during the MDT. Dots indicate the mean durations at conferences with a particular number of patients being discussed. Regression lines are derived from 164 (baseline) and 163 (ISPM) patients per group. ISPM, IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator; MDT, multidisciplinary therapy conference.
Patient demographics of the baseline versus the ISPM cohort
| Baseline | ISPM | P value | |
| No of patients | n=924 (69.5%) | n=405 (30.5%) | |
| No of patients in MDT-MODe | n=164 (50.2%) | n=163 (49.8%) | |
| No of patients per conference | Mean=7.8 (SD=2.9) | Mean=7.4 (SD=2.6) | M-W p=0.74 |
| No of staff per conference | Mean=11.7 (SD=2.7) | Mean=11.5 (SD=2.8) | M-W p=0.85 |
| Patient age (years) | Mean=65.5 (SD=7.4) | Mean=65.9 (SD=7.1) | M-W p=0.48 |
| Postoperative ISUP grade group | M-W p=0.27 | ||
| ISUP 1 | 74 (8.3%) | 11 (3.1%) | |
| ISUP 2 | 424 (47.6%) | 181 (51.3%) | |
| ISUP 3 | 274 (30.8%) | 118 (33.4%) | |
| ISUP 4 | 44 (4.9%) | 15 (4.2%) | |
| ISUP 5 | 74 (8.3%) | 28 (7.9%) | |
| Missing* | 34 (3.7%) | 52 (12.8%) | |
| Postoperative T stage (pT) | M-W p=0.34 | ||
| pT2 | 535 (59.8%) | 215 (61.3%) | |
| pT3a | 258 (28.8%) | 111 (31.6%) | |
| pT3b | 100 (11.2%) | 25 (7.1%) | |
| pT4 | 2 (0.2%) | 0 (0%) | |
| Missing* | 29 (3.1%) | 54 (13.3%) | |
| Preoperative incontinence | M-W p=0.008 | ||
| Continent | 296 (96.7%) | 289 (99.7%) | |
| Incontinent | 10 (3.3%) | 1 (0.3%) | |
| Missing* | 618 (66.9%) | 115 (28.4%) | |
| Preoperative IIEF-5 score | M-W p=0.90 | ||
| Mean=14.2 (SD=9.5) (#missing*=618 (66.9%)) | Mean=14.4 (SD=9.6)(#missing*=122 (30.1%)) | ||
| Preoperative erectile dysfunction - outcome: impotence (IIEF-5 score <12) | LRT p=0.86 | ||
| Frequencies | 133/306 (43.5%) (#missing*=618 (66.9%)) | 121/283 (42.8%) (#missing*=122 (30.1%)) | |
| Prevalence ratios | 1.0 (Ref.) | 0.98 (0.81–1.18) | |
| Response frequency to preoperative questionnaire | χ2 p<0.00 1 | ||
| 309 (33.4%) | 290 (71.6%) | ||
*Percentage missing calculated on the entire cohort.
IIEF-5, International Index of Erectile Function questionnaire; ISPM, IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator; ISUP, International Society of Urological Pathology; LRT, likelihood ratio test; MDT, multidisciplinary therapy conference; M-W, Mann-Whitney U test.
Figure 3MDT-MODe items concerning information presentation. *P<0.05, **p<0.01. (B) MDT-MODe items concerning leadership and team interaction. ***P<0.001. (C) Percentage of staff members actively participating per patient case discussion and decision making in the MDT. *P<0.05 (D) Percentage of patients for which questions were raised during the MDT meeting to repeat already presented information. **P<0.01. ISPM, IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator; MDT, multidisciplinary therapy conference; MDT-MODe, Metric of Decision-Making.
Oncological, perioperative and 12-month functional (urinary, sexual) patient outcomes of the baseline versus the ISPM patient cohort
| Baseline | ISPM | P value | |
| Positive surgical margin | LRT 0.51 | ||
| Frequencies | 251/906 (27.7%) | 98/378 (25.9%) | |
| Prevalence ratios | 1.0 (Ref.) | 0.94 (0.76–1.14) | |
| Nerve-sparing—any | M-W=0.11; χ2=0.13 | ||
| Any nerve-sparing | 805 (88.2%) | 353 (91.2%) | |
| No nerve-sparing | 108 (11.8%) | 34 (8.8%) | |
| Missing* | 11 (1.2%) | 18 (4.4%) | |
| Nerve-sparing unilaterally or bilaterally—dichotomised, with pairwise comparisons | c2=0.005 – OVERALL | ||
| Bilateral | 392 (42.9%) | 140 (36.2%) | c2=0.05† |
| Unilateral | 413 (45.2%) | 213 (55.0%) | c2=0.005† |
| No nerve-sparing | 108 (11.8%) | 34 (8.8%) | c2=0.13† |
| Missing* | 11 (1.2%) | 18 (4.4%) | |
| Pelvic lymph-node dissection | M-W p<0.001 | ||
| No | 543 (60.0%) | 248 (70.1%) | |
| Yes | 362 (40.0%) | 106 (29.9%) | |
| Missing* | 19 (2.1%) | 51 (12.6%) | |
| Lymph-node metastases among patients that underwent pelvic lymph-node dissection | M-W p=0.92 | ||
| No (N0) | 302 (83.4%) | 88 (83.0%) | |
| Yes (N1) | 60 (16.6%) | 18 (17.0%) | |
| Missing* | 0 (0%) | 0 (0) | |
| Erectile dysfunction at 12 months after surgery—outcome: impotence (IIEF-5 score <12) | LRT 0.90 | ||
| Frequencies | 451/604 (74.7%) | 172/229 (75.1%) | |
| Prevalence ratios | 1.0 (Ref.) | 1.01 (0.92–1.09) | |
| Incontinence at 12 months after surgery—outcome: incontinence | LRT 0.98 | ||
| Frequencies | 171/619 (27.6%) | 64/231 (27.7%) | |
| Prevalence ratios | 1.0 (Ref.) | 1.0 (0.78–1.27) | |
*Percentage missing calculated on the entire cohort.
†Pairwise comparison; Bonferroni-Holm corrected for multiple testing.
IIEF-5, International Index of Erectile Function; ISPM, IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator; LRT, likelihood ratio test; M-W, Mann-Whitney U test.